(ALIF-B) AddLife (publ) - Ratings and Ratios

AddLife AB (publ) is a leading provider of specialized equipment, consumables, and reagents to the healthcare, research, education, food, and pharmaceutical industries. Operating through two core segments—Labtech and Medtech—the company delivers a comprehensive range of solutions tailored to diagnostics, biomedical research, and medical devices. Its Labtech division focuses on laboratory analysis equipment, including instruments, plastic consumables, reagents, and cell biology tools, catering to both research and clinical diagnostics. The Medtech segment offers a diverse portfolio of medical devices for orthopedics, wound care, endoscopy, ophthalmology, and assistive technologies, addressing the needs of healthcare providers and patients across various therapeutic areas.

Headquartered in Stockholm, Sweden, AddLife AB (publ) has established a strong presence across multiple regions, including the Nordics, the UK, Ireland, Spain, Italy, and Germany. With a market capitalization of 18,767.06M SEK, the company is recognized for its long-standing history, dating back to its founding in 1906. Its operations are supported by a network of subsidiaries, enabling it to maintain a competitive edge in the life sciences tools and services sector. The company’s strategic focus on innovation, customer-centric solutions, and sustainable growth has positioned it as a key player in its markets.

Based on the provided data, the 3-month forecast for AddLife AB (publ) suggests potential upside momentum, supported by its current price of 154.00 SEK, which is above the SMA 20 (147.77) but slightly below the SMA 50 (155.69). The ATR of 6.21 indicates moderate volatility, suggesting manageable risk levels. From a fundamental perspective, while the high P/E (74.76) and P/S (1.82) ratios highlight elevated valuations, the company’s market position and revenue streams may justify these multiples. However, the relatively low RoE (4.75%) and high P/B (3.54) ratio could signal underlying profitability challenges. Over the next quarter, the stock is likely to remain range-bound between 140 and 170 SEK, with potential breakout opportunities if the company demonstrates improved earnings or revenue growth.